Rush to Judgement: Imaginary Worlds and Cost-Outcomes Claims for PCSK9 Inhibitors

• Egile nagusia: Paul C Langley, Dr (Egilea)
• Formatua: Liburua
• Argitaratua: University of Minnesota Libraries Publishing, 2017-05-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Pricing by the manufacturers of the two PCSK9 inhibitors recently approved by the FDA, evolocumab and alirocumab, has led to an ongoing debate over the value of these interventions in clinical practice. In the US, the Institute for Clinical and Economic Review (ICER) has been in the forefront of tho...